<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Diabetes Investig</journal-id><journal-id journal-id-type="iso-abbrev">J Diabetes Investig</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)2040-1124</journal-id><journal-id journal-id-type="publisher-id">JDI</journal-id><journal-title-group><journal-title>Journal of Diabetes Investigation</journal-title></journal-title-group><issn pub-type="ppub">2040-1116</issn><issn pub-type="epub">2040-1124</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27586093</article-id><article-id pub-id-type="pmc">5009146</article-id><article-id pub-id-type="doi">10.1111/jdi.12500</article-id><article-id pub-id-type="publisher-id">JDI12500</article-id><article-categories><subj-group subj-group-type="overline"><subject>Letter to the Editor</subject></subj-group><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Improvement of glycemic control without severe hypoglycemia in a type&#x000a0;1 diabetes patient undergoing hemodialysis after a change from insulin glargine to insulin degludec</article-title></title-group><contrib-group><contrib id="jdi12500-cr-0001" contrib-type="author"><name><surname>Takahashi</surname><given-names>Nobuyuki</given-names></name><xref ref-type="aff" rid="jdi12500-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jdi12500-cr-0002" contrib-type="author" corresp="yes"><name><surname>Tsujimoto</surname><given-names>Tetsuro</given-names></name><xref ref-type="aff" rid="jdi12500-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jdi12500-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jdi12500-cr-0003" contrib-type="author"><name><surname>Inoue</surname><given-names>Kaori</given-names></name><xref ref-type="aff" rid="jdi12500-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jdi12500-cr-0004" contrib-type="author"><name><surname>Kishimoto</surname><given-names>Miyako</given-names></name><xref ref-type="aff" rid="jdi12500-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jdi12500-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jdi12500-cr-0005" contrib-type="author"><name><surname>Kajio</surname><given-names>Hiroshi</given-names></name><xref ref-type="aff" rid="jdi12500-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="jdi12500-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Diabetes, Endocrinology, and Metabolism</named-content><institution>Center Hospital, National Center for Global Health and Medicine</institution><named-content content-type="city">Tokyo</named-content><country country="JP">Japan</country></aff><aff id="jdi12500-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Division of General Medicine</named-content><institution>Jichii Medical University Graduate School of Medicine</institution><named-content content-type="city">Shimotsuke</named-content><country country="JP">Japan</country></aff><aff id="jdi12500-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Department of Diabetes Research</named-content><named-content content-type="organisation-division">Diabetes Research Center</named-content><institution>National Center for Global Health and Medicine</institution><named-content content-type="city">Tokyo</named-content><country country="JP">Japan</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Corresponding author. Tetsuro Tsujimoto<break/>
Tel.: +81&#x02010;3&#x02010;3202&#x02010;7181<break/>
Fax: +81&#x02010;3&#x02010;3207&#x02010;1038<break/>
E&#x02010;mail address: <email>ttsujimoto@hosp.ncgm.go.jp</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2016</year></pub-date><volume>7</volume><issue>5</issue><issue-id pub-id-type="doi">10.1111/jdi.2016.7.issue-5</issue-id><fpage>805</fpage><lpage>806</lpage><history><date date-type="received"><day>16</day><month>12</month><year>2015</year></date><date date-type="rev-recd"><day>07</day><month>2</month><year>2016</year></date><date date-type="accepted"><day>11</day><month>2</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2016 Asian Association for the Study of Diabetes and John Wiley & Sons Australia, Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley &#x00026; Sons Australia, Ltd</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JDI-7-805.pdf"/><abstract abstract-type="toc" id="jdi12500-abs-0001"><p>Insulin degludec improved glycemic control in a type 1 diabetes patient undergoing hemodialysis.<boxed-text position="anchor" content-type="graphic" id="jdi12500-blkfxd-0001" orientation="portrait"><graphic xlink:href="JDI-7-805-g002.jpg" position="anchor" id="nlm-graphic-1" orientation="portrait"/></boxed-text>
</p></abstract><funding-group><award-group><funding-source>Research from the National Center for Global Health and Medicine</funding-source><award-id>26A&#x02010;201</award-id></award-group></funding-group><counts><page-count count="2"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jdi12500</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:01.09.2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>A 61&#x02010;year&#x02010;old woman was diagnosed with type&#x000a0;1 diabetes at 24&#x000a0;years&#x02010;of&#x02010;age and began hemodialysis at 56&#x000a0;years, owing to diabetic nephropathy. She injected insulin lispro at 5&#x000a0;U before breakfast, 12&#x000a0;U before lunch and 2&#x000a0;U before dinner, and insulin glargine at 4&#x000a0;U before breakfast on hemodialysis and non&#x02010;hemodialysis days. Although her glycated hemoglobin and glycated albumin could not completely explain her glucose level, because she also had renal anemia and hypoalbuminemia, her daily glucose level fluctuated from 30&#x000a0;mg/dL to over 400&#x000a0;mg/dL. She was transferred to Center Hospital, National Center for Global Health and Medicine, Tokyo, Japan, by ambulance because of severe hypoglycemia four times in 6&#x000a0;months, and was admitted to improve her glycemic control. To investigate the cause of unstable glycemic control, we checked insulin antibodies, which were negative. The patient was attached to a continuous glucose monitoring system. Her basal insulin was changed from insulin glargine to insulin degludec. Approximately 3&#x000a0;weeks later, mean glucose levels&#x000a0;&#x000b1;&#x000a0;standard deviation (mg/dL), mean amplitude of glycemic excursion, and <italic>M</italic>&#x02010;value improved from 285.5&#x000a0;&#x000b1;&#x000a0;58.1, 115.7 and 100.2 to 125.9&#x000a0;&#x000b1;&#x000a0;32.6, 82.1 and 4.2, respectively, with insulin lispro (5&#x000a0;U before breakfast, 9&#x000a0;U before lunch, 2&#x000a0;U before dinner) and insulin degludec (7&#x000a0;U before lunch; Figure&#x000a0;<xref rid="jdi12500-fig-0001" ref-type="fig">1</xref>). Six months after discharge, her glucose level is still stable between 90 and 200&#x000a0;mg/dL, and she has had no severe hypoglycemia.</p><fig fig-type="Figure" xml:lang="en" id="jdi12500-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Continuous glucose monitoring results on hemodialysis day and non&#x02010;hemodialysis day after a change from insulin glargine to insulin degludec. Black arrow, time of insulin injection and meal. <styled-content style="fixed-case">BG</styled-content>, blood glucose; <styled-content style="fixed-case">HD</styled-content>, time of hemodialysis.</p></caption><graphic id="nlm-graphic-3" xlink:href="JDI-7-805-g001"/></fig><p>Glycemic control is essential for prevention of diabetic complications in patients with type&#x000a0;1 diabetes<xref rid="jdi12500-bib-0001" ref-type="ref">1</xref>. Poor glycemic control of patients with maintenance hemodialysis is associated with all&#x02010;causes and cardiovascular death, and appropriate glycemic control appears to be required<xref rid="jdi12500-bib-0002" ref-type="ref">2</xref>. However, these patients&#x02019; glucose levels are unstable, and often lead to hyper&#x02010; and hypoglycemia. Possible explanations were increased insulin resistance and reduced gluconeogenesis in diabetes with renal insufficiency. In the present case, unstable glucose level and severe hypoglycemia improved after a change of basal insulin from insulin glargine to insulin degludec without a change in total insulin dose. This result might be attributed to the different mechanisms of insulin glargine and insulin degludec. Insulin glargine has low solubility at neutral pH and complete solubility at acidic pH (pH&#x000a0;4). It forms microprecipitates, and is released continuously into circulation after subcutaneous injection. In contrast, insulin degludec forms soluble multihexamers on subcutaneous injection, resulting in a depot from which insulin degludec is continuously and slowly absorbed into circulation, leading to a flat and stable glucose&#x02010;lowering effect. The unique mechanism of insulin degludec provides a buffering effect against changes in absorption rate, contributing to a stable and more consistent activity. In recent studies, insulin degludec improved daily and nocturnal hypoglycemia in patients with type&#x000a0;1 diabetes<xref rid="jdi12500-bib-0003" ref-type="ref">3</xref>, and the pharmacokinetic properties of insulin degludec were preserved in patients with renal impairment<xref rid="jdi12500-bib-0004" ref-type="ref">4</xref>. This case report might contribute to the improvement in glucose control and hypoglycemia in type 1 diabetes in patients undergoing hemodialysis. Further research on the effect of insulin degludec in such patients is desirable.</p><sec id="jdi12500-sec-0003"><title>Disclosure</title><p>The authors declare no conflict of interest.</p></sec></body><back><ack id="jdi12500-sec-0002"><title>Acknowledgments</title><p>This work was supported in part by Grants&#x02010;in Aid for Research from the National Center for Global Health and Medicine (26A&#x02010;201).</p></ack><ref-list content-type="cited-references" id="jdi12500-bibl-0001"><title>References</title><ref id="jdi12500-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jdi12500-cit-0001">
<collab collab-type="authors">The Diabetes Control and Complications Trial Research Group</collab>
. <article-title>The effect of intensive treatment of diabetes on the development and progression of long&#x02010;term complications in insulin&#x02010;dependent diabetes mellitus</article-title>. <source>N Engl J Med</source>
<year>1993</year>; <volume>329</volume>: <fpage>977</fpage>&#x02013;<lpage>986</lpage>.<pub-id pub-id-type="pmid">8366922</pub-id></mixed-citation></ref><ref id="jdi12500-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jdi12500-cit-0002">
<string-name>
<surname>Ricks</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Molnar</surname>
<given-names>MZ</given-names>
</string-name>, <string-name>
<surname>Kovesdy</surname>
<given-names>CP</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Glycemic control and cardiovascular motality in hemodialysis patients with diabetes A 6&#x02010;year cohort study</article-title>. <source>Diabetes</source>
<year>2012</year>; <volume>61</volume>: <fpage>708</fpage>&#x02013;<lpage>715</lpage>.<pub-id pub-id-type="pmid">22315308</pub-id></mixed-citation></ref><ref id="jdi12500-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jdi12500-cit-0003">
<string-name>
<surname>Birkeland</surname>
<given-names>KI</given-names>
</string-name>, <string-name>
<surname>Home</surname>
<given-names>PD</given-names>
</string-name>, <string-name>
<surname>Wendisch</surname>
<given-names>U</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Insulin degludec in type 1 diabetes A randomized controlled trial of a new&#x02010;generation urtla&#x02010;acting insulin compared with insulin glargine</article-title>. <source>Diabetes Care</source>
<year>2011</year>; <volume>34</volume>: <fpage>661</fpage>&#x02013;<lpage>665</lpage>.<pub-id pub-id-type="pmid">21270174</pub-id></mixed-citation></ref><ref id="jdi12500-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jdi12500-cit-0004">
<string-name>
<surname>Kiss</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Arold</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Ropepstorff</surname>
<given-names>C</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Insulin degludec: pharmacokinetics in patients with renal impairment</article-title>. <source>Clin Pharmakokinet</source>
<year>2014</year>; <volume>53</volume>: <fpage>175</fpage>&#x02013;<lpage>183</lpage>.</mixed-citation></ref></ref-list></back></article>